Regeneron Pharmaceuticals, Inc. with ticker code (REGN) have now 26 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $1,230.00 and $800.00 with the average target price sitting at $1,078.11. Now with the previous closing price of $756.81 and the analysts are correct then we can expect a percentage increase in value of 42.5%. Also worth taking note is the 50 day moving average now sits at $977.55 and the 200 day MA is $1,005.55. The market capitalization for the company is 83.17B. The stock price is currently at: $762.00 USD
The potential market cap would be $118,472,875,681 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 18.83, revenue per share of $128.69 and a 7.41% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
